At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 648 enrolled
Drug / intervention
CT-P17 SC +1 morebiological
Likely dose
CT-P17 SC 40mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Efficacy and Safety of CT-P17 With Humira When Co-administered With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis
In Brief
A Phase 3 clinical trial evaluating CT-P17 SC and Humira SC for Rheumatoid Arthritis. Completed, enrolled 648 participants across 1 site.
Detailed Summary
This is a Phase III Study to Compare Efficacy and Safety of CT-P17 with Humira in Patients With Active Rheumatoid Arthritis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesBulgaria
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
Enrollment StartNov 2018
First PostedDec 2018
Primary CompletionOct 2019
Study CompletionApr 2020
TodayJul 2026
First PostedDec 28, 2018
Enrollment StartNov 26, 2018
Primary CompletionOct 8, 2019
Study CompletionApr 24, 2020
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 7.5 years ago
Interventions
CT-P17 SCbiological
Subcutaneous injection of Adalimumab 40mg every two weeks
Humira SCbiological
Subcutaneous injection of Adalimumab 40mg every two weeks